Lung cancer, Sarcoidosis
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: all patients with histologically proven lung cancer or sarcoidosis who had previously undergone EBUS-TBNA at the University of Miyazaki Hospital between April 2014 and July 2016.
Exclusion criteria
Exclusion criteria: the patients rejected to use the data for the clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The detectability of lesions in three groups according to the number of the stroke movements: the low-number group (20 times), the moderate-number group (25 times), and the high-number group (30 times). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Correlation between the detectability and size of lesions 2)The detectability of lesions of lung cancer and sarcoidosis. 3)The detectability of non-necrotizing granulomas in TBLB and EBUS-TBNA. 4)The rate of contraflow of blood in the EBUS-TBNA procedures | — |
Countries
Japan
Contacts
Faculty of Medicine, University of Miyazaki Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine